$TTRX

Turn Therapeutics updated its investor presentation, highlighting GX-03 clinical progress and a $10.3M cash balance as of June 30, 2026. The company expects Phase 2 topline results for atopic dermatitis in Q1 2027 and has a cash runway into Q3 2027. Key milestones include an FDA meeting in Q4 2026 and Phase 3 initiations in 2027. The presentation also details safety and efficacy signals, financials, and IP status.

Lucid Capital Markets initiated coverage of Turn Therapeutics (NASDAQ:TTRX) with a Buy rating and $24.00 price target, citing 77% upside. The company's GX-03 drug is in Phase 2 trials for atopic dermatitis, with results expected in 2026. TTRX stock has risen 305% in the past six months.

Turn Therapeutics Inc. (TTRX) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. Item 3.02 Unregistered Sales of Equity Securities. As previously disclosed, on October 8, 2025, Turn Therapeutics Inc. (the “Company”) issued to GEM Yield Bahamas Limited a warrant (the “Warrant”) to purchase 1,192,207 shares of the Company’s common stock, par value $0.0001 per s

Turn Therapeutics Inc. (TTRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Turn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results Interim Analysis Supports Expansion of GX-03 Phase 2 Study to a Broader Population of Atopic Dermatitis Patients, Including Patients with Moderate-to-Severe Lesions but Low

Biotech gainers included Zhengye Biotechnology (ZYBT), up about 1,048% after a Nasdaq bid-price noncompliance notice. Advanced Biomed (ADVB) rose over 70% after withdrawing a planned SEC-registered offering. Neuronetics (STIM) gained after naming a new CFO. Armata Pharmaceuticals (ARMP) advanced on Phase 3 AP-SA02 progress. Other movers: Profusa (PFSA), Ridgetech (RDGT), Turn Therapeutics (TTRX).

Turn Therapeutics (TTRX) shares rose 3.8% premarket after expanding its GX-03 Phase 2 atopic dermatitis trial to a broader EASI severity population. The company completed an interim analysis and said efficacy was seen in mild-to-moderate patients (EASI 1.1–7.0), with 71.4% vs 33.3% vehicle achieving Week 4 vIGA-AD success. Final design targets ~120–135 patients; no treatment-related serious AEs reported.

Turn Therapeutics (TTRX) reported interim Phase 2 data for GX-03 in 50 adults with moderate-to-severe atopic dermatitis. According to the company, 92.6% of GX-03 patients achieved EASI-50 at Week 4 vs 65.2% with vehicle; EASI-90 was 44.4% vs 30.4% at Week 4 and 51.9% vs 34.8% at Week 8. No treatment-related serious adverse events were reported.

Turn Therapeutics (TTRX) rose over 20% after interim Phase 2 results for GX-03 in atopic dermatitis, with 92.6% achieving EASI-50 at 4 weeks. Conexeu (CNXU) gained ~19% on preclinical B.R.E.A.S.T. bioprinting progress. Rallybio (RLYB) jumped on plans to acquire Avenzo via a $215M investment. LIXTE (LIXT) surged on an AI energy pivot; Quanterix (QTRX) rose on insider SEC filing.

Turn Therapeutics has secured up to $25 million in growth capital financing from Avenue Capital Group to advance its clinical programs for atopic dermatitis and onychomycosis, with an immediate $7 million tranche. The funding is expected to extend the company's financial runway through the mid-year readout of its Phase 2 trial for atopic dermatitis and support preparations for registrational trials of its lead asset, GX-03. Additional funds are contingent on achieving specific clinical and corporate milestones.

Turn Therapeutics announced corporate and pipeline updates and its 2026 outlook ahead of the 44th Annual J.P. Morgan Healthcare Conference. The company is on track with its Phase 2 trial of GX-03 for atopic dermatitis, expecting interim and topline data in the first half of 2026. Turn Therapeutics also expanded its vaccine pipeline to include an intranasal influenza candidate and anticipates near-term revenue generation in 2026 from its commercial partnership with Medline in wound care.